PolyPid PYPD
NASDAQ PYPD
$5.10 +0.02 (+0.39%)
At close: Aug 21, 2026 · 4:00 PM EDT

PolyPid (PYPD) Net Income towards Common Stockholders (2019 - 2026)

PolyPid (PYPD) posted Net Income towards Common Stockholders of $7.7 million for Q1 2026, down 8.79% sequentially from $8.5 million in Q4 2025, and down 6.53% YoY from $8.3 million in Q1 2025.

PolyPid (PYPD) Net Income towards Common Stockholders (2019 - 2026) Analysis & Trends

PolyPid has reported Net Income towards Common Stockholders for 8 years, with the latest figure at $7.7 million in Q1 2026.

  • Quarterly Net Income towards Common Stockholders fell 6.53% year-over-year to $7.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.5 million (up 36.6% YoY) and the FY2025 annual result came in at $8.5 million, down 0.55% from the prior year.
  • Net Income towards Common Stockholders declined to $7.7 million in Q1 2026 per PYPD's latest filing, from $8.5 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $11.9 million in Q1 2022 and troughed at $0.61 in Q2 2022.
  • A 5-year average of $6.5 million and a median of $7.4 million in 2025 frame the typical range for Net Income towards Common Stockholders.
  • The sharpest annual moves came in 2022 and 2025: Net Income towards Common Stockholders tumbled 100.0% in 2022, then surged 789679900.0% in 2025.
  • Over 5 years, Net Income towards Common Stockholders stood at $6.5 million in 2022, then decreased by 3.01% to $6.3 million in 2023, then surged by 34.43% to $8.5 million in 2024, then dropped by 0.55% to $8.5 million in 2025, then decreased by 8.79% to $7.7 million in 2026.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $7.7 million, $8.5 million, and $7.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn 1.10 Bn
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 1.30 Bn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn 472.00 Mn
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -782.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 237.01 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn 164.49 Mn
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -174.37 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -13.27 Mn
9 Royalty Pharma 27.27 Bn 26.43 Bn - 81.49 Mn
10 PolyPid 113.86 Mn 107.09 Mn - 7.84 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 -23.30 Mn
Mar 31, 2026 7.73 Mn
Dec 31, 2025 8.47 Mn
Sep 30, 2025 7.41 Mn
Jun 30, 2025 9.87 Mn
Mar 31, 2025 8.27 Mn
Dec 31, 2024 8.52 Mn
Sep 30, 2024 7.72 Mn
Jun 30, 2024 1.25
Mar 31, 2024 6.43 Mn
Dec 31, 2023 6.34 Mn
Sep 30, 2023 5.55 Mn
Jun 30, 2023 3.95
Mar 31, 2023 6.02 Mn
Dec 31, 2022 6.54 Mn
Sep 30, 2022 9.12 Mn
Jun 30, 2022 0.61
Mar 31, 2022 11.87 Mn
Dec 31, 2021 13.50 Mn
Sep 30, 2021 9.94 Mn